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Research Protocol 
 
 
Monitoring HAART in HIV-infected patients in Thailand: Comparison of two 
strategies to monitor ARV treatment, based on CD4 cell count or viral 
load, to ensure optimal immunological and clinical outcome and 
preserve future treatment options in AIDS patients  
 
 
 
Summary 
 
Implementation of highly active antiretroviral therapy (HAART) has led to a substantial decrease in 
HIV-related mortality and morbidity. With this important advance, however, has come a monitoring 
and decision-making process whose complexity challenges the medical care system, particularly in 
regions where there are large numbers of HIV-infected patients and relatively limited financial and 
health care resources. Current guidelines emphasize maximal and durable viral load (VL) 
suppression. However, while successful therapy is demonstrated by restoration of immunity, 
treatment failure is usually defined as the inability to maintain undetectable viral load, without regard 
to immune function. This situation often leads to a rapid sequence of therapeutic switches, thus 
narrowing therapeutic options over time. A monitoring strategy driven primarily by the patient's 
immune restoration would most likely be as effective in preventing disease progression, would lead to 
fewer changes in HAART regimens and would be considerably simpler and cost effective.  
 
The primary objective is to compare the clinical outcomes of the standard antiretroviral monitoring 
strategy based on VL (VL-S), with a simpler strategy based on CD4+ cell count (CD4-S). An 
important secondary objective is to compare the ability of these two strategies to preserve treatment 
options.  
 
The proposed study is a multicenter, Phase III, randomized, non-inferiority trial comparing VL-S with 
CD4-S among antiretroviral naive immunocompromised adults treated with a NNRTI-containing 
regimen in Thailand. The study will take place at 29 study sites and the study population will be 700 
HIV infected women or men. Index cases will be women screened within the mother-child prevention 
program, and/or their partners with a CD4+ T cell count between 50 and 250/mm3. For women, 
randomization will take place after delivery. The initial HAART regimen will be a NNRTI containing 
regimen, the subsequent one will be a PI containing regimen. Under VL-S, switching is considered 
when VL rises above 400 copies/ml; Under CD4-S, switching is considered when a relative decline in 
the CD4+ cell count more than 30% from peak values within 200 cells from baseline is observed.  
 
The primary endpoint for monitoring strategy comparison is clinical failure, defined as confirmed CD4 
count below 50/mm3, first or new AIDS-defining event, or death. A secondary endpoint is the number 
of drugs exhausted, taking into account cross-resistance mutations and shared toxicities. A pilot 
pharmacokinetic sub study will evaluate drug levels in the study population. 
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Research Plan 
A. SPECIFIC AIMS 
Current management of antiretroviral (ARV) therapy emphasizes stringent viral load monitoring to 
ensure maximal and durable viral load suppression 13-16. This strategy is costly and labor intensive, 
and often leads to a rapid sequence of therapeutic switches with the consequence of narrowing 
therapeutic options over time17.  
The proposed study is based on the hypothesis that a monitoring strategy driven primarily by the 
patient’s immune restoration would be equally effective in preventing disease progression, would 
be simpler to implement, and would lead to fewer antiretroviral regimen changes thereby 
potentially saving treatment options for patients over time as well as reducing the cost and 
complexity of care. 
This study aims to determine whether it is necessary to measure and follow viral loads to achieve 
optimal results of HAART in a population of therapy-naïve patients, or if it is possible, or even 
preferable, to use only the CD4 cell count as a guide in therapeutic decision-making. The proposed 
comparison of simplified vs. standard monitoring schemes may be analogous to the comparison of 
shorter and longer zidovudine use to prevent mother-to-infant HIV transmission in Thailand, 
conducted by our group in 1997-99 [N Engl J Med 2000, 343:982-991].  The results of that study 
have helped to shape the public health approach to mother-to-infant HIV transmission prevention 
in Thailand, and it is hoped that the results of this proposed study will have a similar effect on 
treatment of HIV-infected adults. 
The proposed study is a multicenter, phase III, randomized, controlled, non-inferiority trial 
comparing a simplified CD4 based antiretroviral monitoring strategy with the standard viral load 
based monitoring strategy among antiretroviral naive immunocompromised adults treated with a 
NNRTI followed by a PI-containing regimen in Thailand. The study will enroll 700 HIV infected 
women or men. The women will be screened during pregnancy and enrolled in the study in the 
postpartum period.  Their partners, if consenting, will be screened at the same time as the women, 
or as soon as possible thereafter and enrolled in the study as soon as they are found to qualify. 
Eligible subjects will have a CD4+T cell count (further denoted CD4) between  50 and 250/mm3. 
The study will be carried out in 29 hospitals throughout Thailand (mainly in Bangkok and the 
eastern and northern provinces of Thailand) as a collaborative effort between Harvard and 
Columbia Universities, the Ministry of Public Health of the Kingdom of Thailand, Mahidol, Chiang 
Mai and Khon Kaen Universities, and the Institut de Recherche pour le Développement (IRD) in 
France. These sites are currently participating in the study conducted by the “Perinatal HIV 
Prevention Trial group” (referred to throughout this proposal as PHPT), a trial of nevirapine (NVP) 
plus zidovudine (ZDV) for the prevention of mother-to-infant transmission of HIV (R01 HD 39615). 
Primary objective: 
To compare the clinical outcomes of a monitoring strategy based on CD4 count (further denoted 
CD4-S) with the standard monitoring strategy based on viral load (VL-S), among antiretroviral 
treatment naive immunocompromised adults initiating therapy with a NNRTI-containing regimen.  
Secondary objectives: 
To compare the ability of the two monitoring strategies to spare ARV treatment options, taking into 
account the number of therapeutic options left and the resistance profile. 
To evaluate the safety and tolerance of highly active antiretroviral therapies in 
immunocompromised Thai adults. 
To analyze the relative contribution of lack of adherence, resistance patterns, drug exposure, 
intolerance, and toxicities, to treatment modifications, and virological and immunological failure. 
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B. BACKGROUND AND SIGNIFICANCE 
B.1 Management of combination antiretroviral regimens for the treatment of HIV/AIDS 
Since the mid 1990s, use of combination antiretroviral treatment regimens, also referred to as 
Highly Active Antiretroviral Therapy (HAART), has radically modified AIDS prognosis 18, 19. These 
combinations are capable of decreasing viral load to extremely low levels and have been 
associated with dramatic decreases in morbidity and mortality. As the eradication of HIV infection 
cannot be achieved with currently available antiretroviral regimens, the objective of therapy is 
maximal and durable suppression of viral replication 20.  Such suppression may then achieve the 
goals of restoration and/or preservation of immunological function, improvement of quality of life, 
and reduction of HIV-related morbidity and mortality 19, 21-25. However, as the concepts of HIV 
disease management continue to evolve and develop with the advent of new studies and their 
findings, treatment guidelines are continuously updated. The following is a brief summary of the 
current consensus as reflected in the 2001 update of the Department of Health and Human 
Services (DHHS) guidelines regarding treatment objectives, criteria for initiation of therapy, and 
monitoring and change of therapy strategies 14. 
Initiation of therapy: Treatment is generally offered to patients who are symptomatic or who have 
fewer than 350 CD4+ cells/mm3 or plasma HIV RNA levels exceeding 30,000 copies/mL (bDNA 
assay) or 55,000 copies/mL (RT-PCR assay), based on the willingness and readiness of the 
individual to begin therapy; the potential benefits and risks of initiating therapy in asymptomatic 
individuals; and the likelihood, after counseling and education, of adherence to the prescribed 
treatment regimen. 
For asymptomatic patients with CD4+ cell counts >350 cells/mm3, the consensus is less clear. 
Robust immune reconstitution occurs in most patients who initiate therapy in this CD4 count range 
and viral suppression may be easier to achieve and maintain. However, toxicities 26-31 and 
adherence challenges may outweigh benefits of therapy 32, 33. Some studies have found sex-
specific differences in viral load and CD4 counts; however it seems that the rate of disease 
progression does not differ in a sex-dependent manner 34-36. 
Monitoring: After therapy is initiated, decisions regarding changes are guided by monitoring viral 
load and CD4 cell counts as well as evaluating the clinical condition of the patient. Although 
individual responses are variable, antiretroviral therapy leads to increases in the CD4 count of 100-
200 cells/mm3 or more, a response generally related to the degree of viral load suppression 19, 21, 24, 
25, 37-41. Partial reconstitution of immune function induced by HAART may allow for discontinuation 
of prophylaxis for some opportunistic infections 42-44. A favorable CD4 cell response can occur with 
incomplete viral load suppression 12, 45-47; conversely, probably because of intercurrent opportunistic 
infections or perhaps as a form of drug toxicity, the CD4 count can remain stable or decrease even 
with complete viral suppression 47, 48. 
Although 70-90% of antiretroviral drug-naive patients achieve viral load suppression 6-12 months 
after initiation of therapy, only 50% of ARV experienced patients achieve similar results 25, 41, 49, 50. 
The rate of viral load suppression is associated with the baseline CD4 cell count, the initial viral 
load, the potency of the regimen, adherence to the regimen and drug pharmacokinetics, prior 
exposure to antiretroviral agents, and the presence of opportunistic infections. Adherence is one of 
the most important determinants of the degree and duration of virological suppression 32, 51, 52. In 
treatment naive patients, non-adherence is usually the cause of the first treatment failure. A high 
degree of adherence is necessary for optimal virological suppression with HAART; several studies 
have shown that 90-95% of doses must be taken for optimal suppression 32, 53. Therefore, when 
proceeding with treatment decisions for patients who are failing therapy, adherence should first be 
assessed to clarify whether the solution is to switch therapies or to reinforce and improve 
adherence.   
Drug resistance: Complexities in managing HAART are compounded by failures in suppressing 
HIV replication in treatment-experienced patients, often an indication of drug resistance.  When 
virological failure has been shown to be associated with resistance to only one component of the 
regimen, it may be possible to substitute individual drugs in a failing regimen 54. However, 
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resistance to more than one agent often emerges during therapy. Of further concern is the 
possibility of broad cross-resistance among drugs within the same class 55-57.   
Drug resistance is detected through genotyping or phenotyping assays1-9. Genotyping assays 
detect drug resistance mutations that are present in the relevant viral genes (i.e. reverse 
transcriptase and protease). Their interpretation requires knowledge of the various antiretroviral 
drug related mutations and their potential for cross-resistance [see Section C.6. for Assessment of 
resistance].  
Phenotypic drug susceptibility assays have the advantage that they directly measure the 
susceptibility of a patient's virus to antiretroviral drugs. Three commercial tests are available today 
(ViroLogic’s Phenosense-HIV, Virco’s Antivirogram, and Viralliance Phenoscript), all of which use 
the technology of HIV-1 resistance test vectors. The vectors are constructed by insertion of 
amplified patient-derived RT and PR viral gene segments into a modified HIV-1 genome that 
carries an indicator gene.  Virus particles, produced by transfecting host cells, are used to infect 
target cells (laboratory cell lines such as MT4 or 293). Drug susceptibility is measured by 
comparing indicator gene activity in the presence of varying concentrations of antiretroviral drugs.  
Phenotypic testing is slower and considerably more expensive. Neither phenotypic nor genotypic 
testing detects minor populations of drug-resistant virus.  
Phenotypic testing has not been validated with the CRF01_AE subtype in Thailand. Moreover, 
despite the intrinsic attractiveness of phenotypic testing, the Narval Trial (ANRS 088), which 
assessed the respective value of phenotypic versus genotypic testing versus clinical judgment for 
guiding drug switching and antiretroviral choice, showed that both tests performed about the same, 
with only a slight benefit of the genotyping test over standard of care and of the phenotyping test in 
patients with limited protease inhibitor experience 58. 
Several groups have examined antiretroviral resistance and resistance testing in non B HIV-1 
subtypes including subtype E (CRF01_AE) 4, 5, 8, 59-63. Clinical isolates from drug-naïve patients 
display a high natural polymorphism of the RT and protease genes which does not appear to affect 
the susceptibility of those viruses to ARV compared to B-subtypes 64, 65. No major new mutations 
linked to NRTI or protease resistance have been found, although some accessory drug resistance 
mutations have been described in non-B subtypes which are distinct from those in B subtypes. The 
clinical significance of this is not yet completely known 59.   
In ARV experienced patients, Sato and al. and Phanuphak have shown that changes in amino 
acids coded by the RT gene from strains recovered after treatment with ZDV and/or ddI were 
identical for isolates of E subtypes to those reported for B subtypes 63.  Even though the pathway to 
resistance may vary, so far mutations associated with resistance to NRTI, NNRTI or PI appears to 
be very similar in isolates of B- and E-subtypes.  
Viral “Fitness”: In the presence of incomplete viral suppression, antiretroviral drug pressure selects 
not only for HIV resistance but, at least in some cases, the emergence of viral strains with reduced 
replicative capacity. This replicative impairment may be reversed, and fitness may improve as 
more mutations accumulate 66. Viral virulence, loosely defined as the ability to deplete CD4+ cells 
in vivo or in vitro, may also be affected by genomic changes in gag/pol. How drug resistance, viral 
fitness, and viral virulence combine to affect CD4+ cell depletion is not well understood. 
Understanding these relationships and the factors that influence them may allow clinicians to better 
manage antiretroviral therapy.  
Assays to measure replicative capacity are under development and include competitive growth 
cultures with replication competent virus 67-70 and single replication cycle recombinant virus assays. 
Assays that attempt to measure virulence/pathogenicity are also under development and include in 
vivo animal models (SCIDhu mouse) 71 and ex vivo, three-dimensional, human lymphoid 
histoculture systems 72. These assays have not been studied in prospective (or any other) clinical 
trials. 
Switching antiretroviral therapy: Criteria for considering therapy changes include: insufficient 
reduction in plasma HIV RNA by 4-8 weeks following initiation of therapy; failure to reach 
undetectable levels of HIV RNA in plasma within 4–6 months of initiating therapy, repeated 
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detection of virus in plasma after initial suppression to undetectable levels (suggesting the 
development of resistance); confirmed increase of plasma HIV RNA not attributable to concurrent 
infection or vaccination; persistently declining CD4 cell numbers, as measured on at least two 
separate occasions; intolerance/toxicity; or clinical deterioration. Other considerations include: 
adherence to medications; remaining treatment options; and preparation of the patient for the 
implications of the new regimen that includes side effects, drug interactions, dietary requirements 
and the possible need to alter concomitant medications. If viral suppression has been achieved but 
the patient experiences intolerance or toxicity, the drug involved should be changed, preferably 
replaced by a drug of the same class with a different tolerance or toxicity profile.  
 
Therapies: In the mid 1980s placebo-controlled trials of ZDV established that antiretroviral 
treatment provided clinical benefit to HIV-infected individuals with advanced HIV disease 73. Later, 
combinations of 2 Nucleoside Reverse Transcriptase Inhibitors (NRTI) provided additional, more 
durable clinical benefit 74. The addition of Protease Inhibitors (PI) or Non Nucleoside Reverse 
Transcriptase Inhibitors (NNRTI) demonstrated further benefit 75-77. Most guidelines recommend a 
combination of 3 ARV drugs 14, 78: two NRTIs with one PI, one NNRTI or another NRTI. Appendices 
6 and 9 provide a detailed outline of the current ARV combinations approved by the FDA with 
additional information relevant to toxicities, drug associations and interactions, pharmacokinetics 
and dosing schedules [see also sections C.2.1 Selection and Enrollment of Subject,] 
 
Host genetics, disease progression and response to therapy: Several studies have shown an 
association between disease progression and host genetics, in particular genetic polymorphism 
involved in the immune response. For example, certain MHC or MBL gene alleles have been 
associated with the severity of infectious diseases such as Hepatitis B, C and HIV 79-84. More 
recently, chemokines receptors/HIV co-receptor gene polymorphism 85-87 has been studied in 
relation to HIV disease susceptibility and progression, the CCR5 delta 32 deletion for example. 
This deletion results in the production of a protein that is non functional as chemokine as well as 
HIV receptor. While homozygous individuals for this mutated gene are highly, but not totally, 
protected against HIV infection, HIV infected heterozygous individuals progress more slowly to 
AIDS 88. Natural variants of the CCR5 promotor gene have also been associated with modifications 
of HIV disease progression 89-92. Natural ligands of the CCR5 genes (Mip 1a, Mip 1b and RANTES) 
as well as some alleles of the RANTES gene may also be associated with susceptibility or disease 
progression 93, 94. Associations with other receptors or cytokine genes are also being studied 95-98. 
Pharmacogenetics is an also rapidly expanding research field and recently, important physiological 
interactions involving different ARV drugs, have been reported. A report from the Swiss HIV Cohort 
study demonstrated a significant difference in drug concentrations of ARV drugs between patients 
with different allelic variants of the Multidrug-resistance transporter gene MDR1 99. The frequency 
of this functional polymorphism is significantly influenced by ethnicity; however, Caucasian and 
Asian populations have a similar polymorphism distribution 100. The NNRTIs and PIs are 
metabolised by the hepatic cytochrome P450 enzyme system, which is composed of several 
subfamilies with several different isoforms. CYP3A4 is one of the predominant P-450 isoforms.  
Several allelic variants of CYP3A4 have been identified but no clear relationship between variants 
and drug disposition has been observed 101. Also, abacavir hypersensitivity has been related to 
genetic factors in a Caucasian population 102, but their predictive values across populations are 
unknown.  
 
C. RESEARCH DESIGN AND METHODS 
C.1 Rationale 
According to our current understanding of HIV disease pathogenesis, the optimal way to delay 
progression to disease is to completely suppress viral replication. Theoretically, any regimen that 
does not fully suppress viral replication (currently defined as a viral burden below 50 copies/mL on 
standard assays) will allow for the selection of resistance mutations 119, 120 leading to resistance to 
the current drugs and ultimately cross-resistance to other drugs in the same class. 
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However the objective of total viral suppression is not achieved in all individuals who receive 
HAART. In clinic populations, the rate of virological failure after 24-48 weeks of first-line HAART 
varies from 20 to 40%.  In clinical trials, failure rates may be lower, in the range of 15-20% 19, 121. 
Moreover, patients with virological failure in the initial regimen have lower rates of complete viral 
suppression with subsequent regimens 41, 49, 122, 123.  
Virological failure is not necessarily associated with immunological or clinical failure. For example, 
it has been noted that in patients who experience virological rebound while taking a PI-based 
regimen, viral load rarely returns to pre-treatment levels 124. This indicates that, at least for a period 
of time, under continuing drug pressure, resistant viral strains less able to replicate persist, as has 
been demonstrated in vitro 125, 126.  
The proposed protocol is designed to determine whether it is necessary to measure and follow viral 
loads to achieve optimal results of HAART in a population of therapy-naïve patients, or if it is 
possible, or even preferable, to use only CD4 counts as a guide to therapeutic decision-making.  A 
strategy basing treatment decisions on viral load measurements and attempting complete viral 
suppression in all patients may lead to fast and multiple changes in therapy. In contrast, a 
monitoring strategy based on the evolution of the CD4 count allowing for a certain level of 
replication before changing therapy may be safe and more effective in preserving future treatment 
options, provided that the immune system is not harmed. 
Two direct observations support the practice of monitoring antiretroviral therapy based on CD4 
count: 
1) For patients taking HAART, current CD4+ cell count is a better measure of short-term risk of 
disease progression than viral load 127-130.  2) The sustained CD4 T-cell benefit in patients with 
rebounding viremia during PI therapy appears to predict a sustained clinical benefit 12,124, 131-133. 
The Swiss HIV Cohort Study, for example, examined the positive effect of HAART even in the 
absence of optimal control of viremia. Patients were categorized based on their virological 
response to therapy: virological responders without rebound, patients with an initially undetectable 
viral load followed by a viral rebound, and patients who never reached an undetectable viral load. 
Clinical progression in all three groups was rare over 2 years of follow-up, even in patients with 
evidence of ongoing viral replication 124.  
The virological mechanism underlying the preserved virologic and immunologic benefit despite the 
emergence of drug resistant virus remains unclear and is likely to be multifactorial 134. Several 
virus- and host-related factors may be involved including pharmacokinetics, adherence, and tissue 
penetration; viral replicative capacity or “fitness”; generation and maintenance of an effective HIV-
specific immune response; reduced generalized immune activation and, as a consequence, 
reduced availability of susceptible target cells; and maintenance of gains in immune reconstitution 
despite the persistence of detectable viremia.  
To illustrate our genuine uncertainty about the outcomes of the proposed monitoring strategies, we 
simulated a scenario where a population initiating HAART would be followed for three years while 
submitted to either VL-S where the switching point is reached when VL rises above 400 copies per 
mL, or to CD4-S, where the switching point is reached when CD4 count declines more than 30% 
from peak values within 200 cells from baseline. This simplified scenario assumes that under VL-
S, the time under HAART spent while in virological failure is short, that new regimens are invariably 
successful, at least initially, and that there are no drug/family overlap between first and subsequent 
regimens.  
Based on published data 19, 39, 41, 50, 121, 124, 129, 130, 135, we assumed a rate of virological failure of 25% 
yearly on the initial HAART regimen and a 35% yearly rate on any subsequent regimen. We also 
assumed that the rate of immunological failure would be 7%, a figure consistent with our 
observation in the cohort of patients receiving NNRTI based HAART in the PHPT hospital 
networks, and recent data would suggest an extended immunological benefit under a PI based 
treatment regimen even in the presence of viral replication 49, 136-138 
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With the above assumptions, at the end of a three year follow-up, approximately 42% of 
the patients randomized in the VL-S monitoring arm would still be on the initial therapy, 
37% on the second line regimen, 18% on the third and 3% on the fourth. The average 
number of switches would have been 0.8 per patient. Finally, it would be expected that the 
percentage of time spent on each HAART regimen would have been 65% for the initial 
regimen, 26% for the second line, 7% for the third and 1% for the fourth. 
The results under the CD4 monitoring strategy would be strikingly different: approximately 
88% of the patients would still be under the initial regimen after 3 years, and 11% under 
the second line regimen. The average number of switches would have been 0.2 per 
patient, 88% of the time on HAART would have been spent under the initial regimen and 
12% under the second line regimen. 
This scenario would suggest that patients monitored based on CD4 count are at advantage 
compared to patients monitored based on viral load. However, a main concern about delayed 
switches is the sequential accumulation of drug resistance mutations that may diminish the 
chances of viral re-suppression with successive HAART regimens. As described in the background 
section, the emergence of drug resistance mutations after clinical detection of viral rebound is 
variable. In general, the isolated lamivudine (3TC) and non-nucleoside reverse transcriptase 
inhibitor (NNRTI) mutations occur soon after viral rebound, whereas mutations associated with 
resistance to nucleoside analogues (except 3TC) and protease inhibitors (PIs) emerge after more 
prolonged periods of virologic relapse 54, 139, 140. Although it may be hypothesized that subjects 
remaining on a partially suppressive regimen will accrue additional resistance mutations to the 
current regimen, it is also likely that a substantial proportion of patients switched early will 
experience virologic rebound on their new regimen. The relative risk of the accumulation of more 
mutations to an “old” regimen versus the development of resistance to “new” drugs requires 
evaluation in a randomized trial. Moreover, understanding why patients continue to maintain some 
degree of partial viral suppression despite the emergence of drug resistance will allow for the 
development of therapeutic strategies aimed at determining when to switch, when to continue, and 
when to stop antiretroviral therapy. 
The evaluation of a simpler monitoring strategy is particularly relevant in Thailand. With recent 
global emphasis on the treatment of infected individuals, the large number of candidates for such 
programs will place an equally large burden on the medical system. Of the various components of 
this burden, cost of drugs, which has decreased dramatically over the past two years, is only one 
part of the problem. Of at least equal, and perhaps greater, importance is the education of health 
care practitioners and patients in the complex management of multiple-drug HIV therapy, 
equipping of laboratories, training of laboratory personnel, and finally implementation and cost of a 
system for monitoring viral load and CD4 count. As the country is embarking on this ambitious 
program, it is of utmost importance to determine the ARV management strategy that will be most 
beneficial in the long term for patients in the Thai context [See section C.15. ARV management 
strategy for implementation in the Thai Context]. 
Assessing simplified yet effective monitoring strategies will also be important for countries less 
advanced than Thailand. The year 2001 marked a turning point in the approach to AIDS prevention 
and care with the increased availability of generic drugs, the agreement by five large 
pharmaceutical companies to significantly reduce the cost of antiretroviral drugs, and a pledge by 
the international community at the 26th special session of the United Nations General Assembly to 
drastically increase its financial and technical support to poor countries affected by AIDS (UN, June 
2001).  Universal access to antiretroviral therapies will be one of the major public health 
undertakings of the next decade; yet few physicians are skilled in the use of antiretrovirals. In many 
situations, the health infrastructure is not fully prepared to train health personnel, distribute the 
drugs, inform and evaluate patients, initiate therapy and monitor viral response, immune status or 
side-effects of the drugs 141. Current guidelines from the World Health Organization emphasize the 
role of clinical and immunological monitoring of antiretroviral therapy 142. Groups working in 
developing countries are assessing strategies to optimize resources and increase patients’ 
chances for a sustainable response to antiretroviral therapy 143, 144. In this context, the 
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documentation, by comparison to current standards, of a CD4 based monitoring strategy that may 
be equally safe, more practical, and spare more future treatment options will be extremely useful. 
In summary: If patients are immunologically well and can tolerate their current therapy, avoiding 
premature switches is likely to expose them to fewer regimens, thus averting new toxicities, new 
drug interactions, and new adherence issues. It also has the potential of preserving more drug 
options for current as well as future use. Thus, besides the obvious benefit of demonstrating the 
effectiveness of a monitoring strategy that is likely to be easier to implement in resource limited 
regions of the world most affected by HIV, we have a genuine uncertainty as to which strategy 
would be more beneficial in terms of clinical outcome and therapeutic options spared. This 
question can only be resolved through a carefully monitored clinical trial. 
 
C.2. DESIGN  
The proposed study is a multicenter, Phase III, randomized, non-inferiority trial comparing the 
standard viral load based antiretroviral monitoring strategy with a simpler CD4 based monitoring 
strategy among antiretroviral naive immunocompromised adults treated with a NNRTI-containing 
regimen in Thailand. In 29 study sites, the study population will be 700 HIV infected subjects 
(women screened during pregnancy, and/or their partners) who have a CD4 count between 50 and 
250/mm3. 
Within each study site and patient stratum (postpartum women and male partners), subjects will be 
randomly assigned to one of two monitoring strategies:  
• VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed 
when VL is confirmed (within one month) above 400  copies per mL. 
• CD4-S, the alternative CD4 based monitoring strategy where switching is performed when 
a confirmed (within one month) relative decline in CD4 count of more than 30% from peak 
values is observed within 200 cells from baseline. 
The initial HAART regimen will be a NNRTI+NRTI containing regimen and the second line regimen 
will be a PI containing regimen, subsequent regimens will be chosen individually based on 
tolerance, previous drugs used, resistance profile, and drugs available. Patients will be followed 
until the end of the study (5 years for the first enrollee, three years for the last enrollee). 
For patients who reach their predefined viral load or CD4 threshold for switching, laboratory results 
will be confirmed within one month and, before any change of therapy is made, causes for viral 
rebound or immunological deterioration will be investigated, with particular attention to adherence 
or tolerance issues, toxicities and co-infections. Upon confirmation of laboratory results, the 
treatment regimen may be switched to the next scheduled regimen. 
 
C.2.1. Selection and Enrollment of Subjects 
The study population is HIV-infected women identified through the MOPH Prevention of Mother to 
Child Transmission (PMTCT) program and/or their partners, consulting at one of the study sites, 
with a CD4 count between 50 and 250/mm3 and who otherwise satisfy entry criteria. Based on 
current figures of HIV prevalence at the study sites and enrollment in PHPT-2, we estimate that 
about 1500 HIV pregnant women will be willing to undergo pre-enrollment evaluation. After 
appropriate counseling, pregnant women will be encouraged to invite their partner to come to the 
hospital for information, counseling, and HIV testing. Participation of both women and their partner 
in the study will be encouraged if they meet inclusion criteria, but joint participation will not be a 
prerequisite for enrollment of either one. Data from our previous trials suggest that about 21% of 
those women will meet entry criteria.  
Pre-enrollment evaluations for the women will take place during pregnancy and as soon as 
possible for their partner. Standard ARV prophylaxis for the prevention of mother to child HIV 
transmission will be provided to all pregnant women. If the clinician judges that a woman needs to 
start HAART during pregnancy, after careful evaluation of the expected risks and benefits HAART 
will be offered, but she will not be randomized in the study. If nevirapine is used during labor for 
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PMTCT, theoretical considerations would warrant starting maternal HAART right after delivery in 
order to prevent emergence of NVP resistance mutations. Moreover, a previous study in Thailand 
has shown that women in PMTCT programs hope to continue ARV therapy for their own health 
after delivery 145. Taking into account these considerations, women who qualify for study entry will 
be counseled during pregnancy, and if they appear ready and willing to start they will be 
encouraged to initiate therapy as soon as possible after they have delivered.  
HIV infected women and partners who do not fulfill enrollment criteria will be followed on an 
outpatient basis to receive counseling and monitoring of their health condition. Patients with CD4 
above 250 cells per mm3 will have a CD4 count performed every six months. If the CD4 count 
drops below 250 cells per mm3, enrollment in the study will be proposed to the patient. Patients 
with a CD4 count lower than 50 cells per mm3 will receive treatment through the MOPH program 
but will not be eligible for randomization in the study.  
Justification for implementing this study in the Mother and Child Health framework 
Following the results of PACTG 076 114, 146 and the clinical trials conducted in Thailand showing the 
efficacy of ZDV prophylaxis for the prevention of perinatal transmission of HIV, the Health 
Promotion/Mother and Child Health Division of the Department of Health and the Department of 
Communicable Diseases Control of the MOPH implemented a nationwide program to prevent 
perinatal HIV transmission, with universal access to counseling, HIV testing, ZDV prophylaxis and 
infant formula feeding. This program has already led to a decline in the number of reported 
pediatric AIDS cases. The proposed study builds upon this success, using the Mother and Child 
Health framework as an entry point for initiating therapy in immunocompromised HIV infected 
women and/or their partners. In addition, antenatal clinics are the only location where adults are 
systematically screened for HIV infection, and many women, and their partners, learn in this setting 
for the first time of their HIV status. 
In April 2001, at the end of the Third International Symposium on Pediatric AIDS in Thailand 
organized by PHPT and the Ministry of Public Health, participants decided to submit a Declaration 
to the Minister of Health requesting antiretroviral treatments for immunocompromised women 
diagnosed during pregnancy. In November, 2001 the Ministry of Public Health officially designated 
Mother and Child Health as the first priority for its expanded access program to antiretrovirals [See 
Section D15. ARV management strategy for implementation in the Thai context]. Parents are a 
particularly appropriate target for therapy because of the importance of their role as parents of both 
infected and uninfected infants. 
Justification for the chosen regimens 
The chosen HAART regimen for initial therapy is a 2NRTIs+NNRTI containing regimen specific 
components of which, d4T or ZDV or TDF or 3TC/FTC, or NVP or EFV, will be selected depending 
on the patients needs (toxicity, sex, co-infections, tolerance) and availability. Such a NNRTI 
containing regimen appears most appropriate because: 1) The recently published AACTG 384 [N 
Engl J Med 2003;349:2293-303] has demonstrated that a NNRTI compared to a PI containing 
regimen gave optimal results as first line therapy; 2) NNRTI based regimens are now 
recommended as first line therapies by both the Thai and International treatment Guidelines.  
 
The second line regimen will be a PI containing regimen: 2NRTIs selected based on the first line 
and indinavir boosted with ritonavir (IDV/r).  Both regimen are appropriately potent combination in 
the  50-250 CD4 range; 11,75, 76, 122, 147-149; GPOvir (d4T/3TC/NVP), 3TC, NVP, EFV, ZDV and IDV/r 
are available in Thailand10 with convenient bid dosing. Through reduced dosing because of 
patients’ lower average weight for IDV/r, it is the most inexpensive PI based regimen in Thailand. 
Subsequent regimens will be chosen individually based on tolerance, previous drugs used, 
resistance profile, and drugs available. 
 
C.2. 2. Eligibility, Inclusion and Exclusion Criteria 
Eligibility Criteria. Patients will be eligible if they have confirmed HIV-infection, intend to be followed 
at a study site for the duration of the study, can provide informed consent, and, for women, are 
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willing not to breastfeed and to comply with an effective contraception method for the duration of 
the study. 
Inclusion Criteria. Written informed consent (if age<18 years, legal guardian’s consent and 
patient’s assent); HIV-1 infection documented by two HIV antibody tests on two different blood 
draws; confirmed CD4+ cell count above 50 and lower than 250 cells/mm3 within 6 months prior 
to study entry; naive to antiretroviral therapy (except exposure to zidovudine during pregnancy 
and/or nevirapine during labor); willingness to initiate, modify, or stop antiretroviral therapy in 
accordance with the randomized monitoring scheme assignment; subject’s understanding that 
study drugs will be supplied only during participation in the study, and reasonable certainty that 
he/she will be able to access HIV treatment after the study.  
Exclusion Criteria. For women, pregnancy. Current active substance or alcohol abuse that would 
interfere with participation in the study. Chemotherapy for active malignancy.  Active opportunistic 
infection and/or serious bacterial infection or unstable or severe medical condition within 14 days 
before randomization.  Chronic malabsorption or chronic diarrhea (> 6 loose stools/day for > 14 
days within one month of entry) or recent (within 7 days) unresolved acute diarrhea. The following 
laboratory values: hemoglobin < 8.0 mg/dl, absolute neutrophil count < 1000 cells/mm3, ALT, AST 
or total bilirubin value > 5.0 x ULN, serum creatinine > 1.0 x ULN, platelet count < 50,000/mm3, 
pancreatic amylase >2.0 x ULN, or total amylase > 2.0 X ULN plus symptoms of pancreatitis. Pre-
existing diabetes mellitus (prior gestational diabetes is allowed). Acute hepatitis within 30 days of 
study entry. Any clinically significant diseases (other than HIV infection) or clinically significant 
findings during screening medical history or physical examination which, in the investigator’s 
opinion, would interfere with the conduct of the study. Psychosocial environment or condition 
which, in the physician’s opinion, makes adherence to the protocol highly unlikely. 
HIV infected women and partners who are not willing to participate in the study or those who do not 
fulfill enrollment criteria, in particular those with a CD4+ cell count lower than 50, will receive 
counseling on HIV/AIDS treatment and will be cared for by the MOPH Mother and Child Health 
services. In December 2001, the MOPH launched a new program to provide ARV treatment 
through the Mother and Child Health care delivery system to women diagnosed with HIV during 
pregnancy and their partners. Patients with CD4+ cell count above 250 will continue to have a visit 
and a CD4+ cell count every six months for the duration of the enrollment period. If the CD4+ cells 
count drops below 250/mm3, enrollment in the study will be considered.  
Allowed/Disallowed Medications.  
The list of contraindicated associations allowed and disallowed medications for each antiretroviral 
drug is provided in the Appendix 9 (Toxicity grading and management) and Appendix 10 (Drug 
regimens). 
Opportunistic Infections (OI) Prophylaxis: Prophylaxis and treatment of OIs (in particular PCP, 
tuberculosis, cryptococcal meningitis, and P. marneffei, the most frequent OIs in Thailand) will 
follow the Thai recommendations regularly adapted from international guidelines including 
recommendations on the management of tuberculosis treatment and HAART 150. 
 
C.3 Study Visits and Laboratory Evaluations 
The pre-enrollment visit for women will take place as early as possible after routine prenatal 
counseling and HIV testing for the prevention of Mother to Child transmission of HIV. Evaluations, 
enrollment and HAART initiation will take advantage of the routine follow-up schedule of visits for 
women participating in the national perinatal HIV prevention program. As much as possible, study 
visits after delivery will follow the routine schedule of postpartum care. Visits for the woman and 
her partner will be coordinated so as to facilitate participation and adherence to the study 
procedures. The family approach for initiation and follow up of HAART for women and partners will 
involve a specifically trained team of physicians, counselors, nurses and technicians from the 
departments of obstetrics, pediatrics, internal medicine and laboratory at each site. 
Routine laboratory tests, including HIV ELISA, lymphocyte subsets, hematology and chemistries, 
will be performed in the study site laboratories, following the schedule shown in Table 1. The PHPT 
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laboratory and the Faculty of Associated Medical Sciences, Chiang Mai University will ensure 
training and quality control. Viral loads will be performed at the PHPT Laboratory. CD4 counts will 
be performed at selected hospital sites where quality and consistency of results have been 
assured and are monitored on a regular basis. Quality control for viral load testing will be 
performed on a monthly basis using an independent run control from the International Molecular 
Services (IMS). Every 3 months quality control for CD4 testing will use the proficiency panel from 
UKNEQAS  [See appendix 7 for Laboratory Procedures].  Quality control for hospital hematology 
and chemistry laboratories is carried out through the Bureau of laboratory quality standard, 
Department of Medical Sciences, Ministry of Public Health. 
C.3.1. Pre-enrollment Process 
All HIV-positive women and /or partners identified at one of the 29 sites through the PMTCT 
program are offered counseling on PMTCT and HIV/AIDS and HIV confirmation serology and CD4 
cell count measurement will be provided. At a subsequent visit, the internist will assess the need 
for OI prophylaxis and ARV treatment according to the MOPH guidelines for all identified 
immunocompromised patients. A special counseling session on ARV treatments will be offered to 
explain in detail the possible regimens, their constraints and potential side effects, and the 
importance of adherence. Patients with a CD4 count between 50 and 250 cells/mm3 are eligible for 
the proposed study. They will be provided an appointment with a trained counselor to explain the 
study in details. All patients will be informed about the potential risks and benefits of the two 
monitoring strategies of ARV treatment in the study [See Section “Ethical considerations”]. Their 
participatory consent will be requested in writing. After consent, the baseline assessment for 
eligibility will be carried out [See Section C.2.2 for Eligibility, Inclusion and Exclusion Criteria]. A 
careful history of previous antiretroviral use will be taken. A clinical examination and baseline 
laboratory workup will be performed, including blood counts, renal, pancreatic and liver function, 
metabolic markers, e.g., glucose, cholesterol, and triglycerides, CPK, co-infection assessment 
(HBV, HCV), assessment of several infections (toxoplasmosis, syphilis, Mantoux test, chest 
radiograph, and CMV according to the Thai 2001 guidelines for the management of HIV infected 
patients), and HIV viral load measurement.  
Women under ARV prophylaxis during pregnancy will be routinely followed monthly until the 34th 
week of pregnancy and then once every 2 weeks until delivery, according to the schedule 
recommended by the Ministry of Public Health. At delivery circumstances, mode of delivery, and 
any delivery complications will be recorded. Hospital staff will be specifically trained about 
confidentiality. Each site will maintain records of reasons for subject ineligibility or non-
participation. As in the ongoing PHPT trial, special attention will be paid to needs of patients 
belonging to Thai minorities who may not be comfortable with standard Thai language (translation 
of documents, involvement of People with AIDS groups, availability of translators and training of 
counselors).  
 
C.3. 2. Study Entry, Randomization  
Patients will be given the results of laboratory tests performed at the previous visit. Counseling 
about OI prophylaxis and ARV treatments (in particular the first line regimen) will be reinforced. To 
ensure that patients are fully informed, they will receive in-depth information on the two monitoring 
strategies, treatment, and study schedule. Patients will be reminded that they can withdraw from 
the study at any time without compromising their future care. Partners may be randomized at this 
visit if they meet all selection criteria. Randomization of eligible pregnant women will take place, 
whenever possible, right after delivery when they are still hospitalized [See Section C.8 for 
Randomization Procedures]. ARV treatment will be initiated just after randomization. Patients will 
be given a one-month supply of antiretroviral treatment. 
 
C.3.3. Follow-up 
Study visits will take place two week after randomization and every month thereafter with a study 
nurse/counselor. Visits will include physical exam, counseling, adherence and tolerance 
evaluation, review of lab results and drug procurement.  In addition, at 1 month and every 3 
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months thereafter until the end of the follow-up period, the physician will perform physical exam, 
assess HIV/AIDS related signs and symptoms as well as OIs and other infections, and review the 
blood tests performed within the previous month. These blood tests include: hematology, 
chemistry, CD4 counts, as well as drug dependent toxicity evaluations (SGOT, SGPT, alkaline 
phosphatase, bilirubin, creatinine, amylase, CPK, with triglycerides, cholesterol, and glucose 
measured every 6 months). A plasma sample will be also collected and stored frozen for viral load 
evaluation. For patients in the VL-S arm, real time viral load evaluation will be performed. For 
patients in the CD4-S arm reaching the CD4 switching criterion, viral load will be performed for final 
analysis. Patients may be seen more often as needed, in particular for toxicity, intolerance, HIV/OI 
related signs and symptoms or management of therapy. Other evaluations may be performed 
depending on the patient’s condition. 
 
Table 1. Summary of Clinical and Biological Study Follow-Up 
 Screening period 
Pre-
Entry 
Entry1/ 
Randomization 
2nd 
week 
1st 
month 
Every 
month 
Every 3 
months 
Questionnaire X X X X X X X 
Physical Exam X X X X X X X 
Counseling X X X X X X X 
HIV Serology X X      
Consent  X      
Adherence / tolerance to ARV    X X X X 
Hematology 2 Chemistry 3  X   X  X 
CD4+ cell count X X     X 
Viral load 4  X     X 
1 Pregnant women may be randomized after delivery. 
2 Hematology includes: Hemoglobin, hematocrit, RBC, MCV, WBC, platelets, reticulocyte count. 
3  Chemistry includes: SGOT/SGPT, alkaline phosphatase, bilirubin, creatinine, amylase, CPK, 
triglycerides, cholesterol, glucose measured every 3 or 6 months. 
4 Only the VL-S arm 
 
 
 
Switching criteria and additional visits  
In patients assigned to VL-S, after initiation of HAART (or any new regimen during the study), VL 
will be performed every three months.  At month 3, if less than a ten-fold reduction in plasma HIV 
RNA is observed, patient adherence will be carefully re-assessed, and a new VL will be measured 
at 4 months. If there is still less than a ten-fold reduction in plasma HIV RNA (and if the HIV RNA is 
above 400 copies/mL) the HAART regimen will be switched. Once a satisfactory VL has been 
reached (below 400 copies/mL), if a viral load increase above this threshold of 400 copies/mL is 
observed, a confirmatory viral load test will be performed within one month. Patients with a 
confirmed increase in viral load will be switched to second or third line treatment.  In patients 
assigned to CD4-S, after initiation of HAART (or any new regimen during the study), switching will 
be performed when a confirmed (within one month) relative decline in CD4 count of more than 30% 
from baseline values within 200 cells from baseline is observed. After the first 6 months, if a 30% 
relative decline of CD4 counts from the “peak value” (the highest average of two consecutive CD4 
counts) within 200 cells from baseline is observed, a confirmatory CD4 will be performed within 
one month. Patients with a confirmed decline in CD4 will be switched to second or third line 
treatment. In case of fever or intercurrent infections, CD4 and viral loads will be interpreted 
according to the clinical context and if necessary performed again when the condition has 
resolved. 
If the CD4 decline or the VL increase is not confirmed, patients will continue the treatment and 
follow-up schedule. In all patients reaching the switching criteria, adherence and tolerance will be 
reassessed carefully before any decisions are made [See section C.4 for Adherence assessment 
and case management and section C.5. for Tolerance and safety assessment and case 
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management]. After treatment modification, a visit will be planned one week later to assess 
tolerance and adherence. Follow up will then resume with the original three monthly schedule of 
clinical and biological evaluation visits.  
Before any confirmatory measurement (Viral load or CD4 count), patients will be instructed not to 
take their treatment the morning of the planned visit so that plasma can be stored frozen for 
retrospective analysis of drug trough levels. If needed the co-investigator can schedule extra 
visits/evaluations. 
 
C.3.4 Repository of blood specimens 
Samples, identified by code, will be stored in -70°C or -20°C freezers in the PHPT-IRD 054 
repository building located in 31/1 Samlan Road Soi 1, Muang, Chiang Mai until the end of the 
study and only used for the study i.e. 6 months after all patients have completed the follow-up 
period which is the time necessary for laboratory tests to be performed and controlled and the 
results to be published. Patients can withdraw their blood sample from the sample repository at 
any time, and it will be immediately destroyed. No other studies will be carried out on these 
samples. If other studies were deemed necessary for a major scientific reason, we would request 
additional consent and this would be submitted as a specific study to the Ethical Review 
Committee for Research in Human Subjects. 
The table below summarizes the quantity of blood drawn for each test. 
 
Tests 
Amount 
(ML) 
HIV Serology 3 mL 
Hematology  3 mL 
Chemistry  3 mL 
CD4+ cell count 4 mL 
Viral load and 
genotyping * 
6 mL 
 
* In the rare case where viral load would be too low to perform genotyping, another blood draw at a 
subsequent visit may be necessary. 
 
C.4. ADHERENCE ASSESSMENT AND CASE MANAGEMENT 
We plan to implement a robust adherence assessment and management program to minimize the 
role of non-adherence as a possible cause of treatment failure before proceeding with switches.  
Assessments of adherence will provide feedback for how best to improve and/or maintain high 
adherence. Adherence will be assessed monthly using a combination of subjective and objective 
measures including pill count 151 and detailed self-report questionnaire 53, 151-155. Adequate 
adherence will be defined as taking at least 95% of doses during each monitoring period. [C.7. 
Operational aspects of delivering HAART in Thailand; Appendix 8 for adherence assessment] 
Counselors will be trained to develop culturally appropriate strategies to proactively assist and 
support patient efforts to adhere to the ARV regimens. They will meet individually with patients to 
provide a non-judgmental arena for information and support during ARV treatment. Counselors’ 
responsibilities include: 1) patient education to explain the disease and treatment, purpose of 
therapy, medication regimens, management of side effects, the association of CD4 and viral load 
levels with treatment progress, risk of resistance, and importance of perfect adherence; 2) 
development of an individualized plan to integrate the regimen into patients’ daily activities, 
including the use of medication boxes and personalized calendars as tools. Continuous 
reinforcement and follow-up will ensure optimal adherence. 
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Case management. Adherent patients will be encouraged to maintain their high levels of 
adherence.  For non-adherent patients, the first step will be to reinforce adherence counseling.  
Counselors will target episodes of non-adherence by working with patients to devise strategies to 
prevent recurrent missed doses. However, if there is consensus between the physician, counselor, 
and patient that non-adherence is due to intolerance to a particular regimen, therapies will be 
modified, if possible, using drugs of the same class [See Section C.5 for Tolerance and safety 
assessment and case management]. 
For patients on a first line regimen who satisfy criteria for switching therapy and who are non-
adherent despite counseling efforts, a second line regimen will be prescribed. If the patient remains 
non-adherent and reaches criteria for switching to a third line regimen, discontinuation of treatment 
will be considered 156. Despite the decision to discontinue treatment, the patient will continue to be 
followed within the study. [See appendix 9 for side effects assessment] 
 
C.5. TOLERANCE AND SAFETY ASSESSMENT  
Management of toxicities will be discussed and reviewed with the clinical staff during on-site 
training that will be organized prior to starting the study. Additionally, these topics will be described 
in detail in the Manual of Operations [See Appendix 9 for Management of toxicities].  
Safety and tolerance of therapy will be evaluated at each monthly visit.  Laboratory results and 
clinical data will be evaluated every three months. If the patient presents with confirmed intolerance 
or side effects to one drug, that drug will be replaced by another drug in the same class. In case of 
intolerance, ZDV will be replaced by d4T, NVP by EFV, and Indinavir/Ritonavir by Nelfinavir. 
Adverse events reporting. Severity of clinical and biologic toxicities will be evaluated according to 
standard assessment criteria that will be described in the Manual of On-site Operations [see 
Appendix 3 for PHPT-2 Manual of On-site Operations]. These are modeled after the toxicity tables 
developed by the ACTG.   
Serious adverse events. Any serious adverse event and grade 4 toxicity will be immediately 
reported to the Study Coordinating Center (SCC), whether or not the event is considered to be 
related to ARV treatment. The SCC office can be reached 24 hours a day by a paging system and 
phone. All these events will be reported within 48 hours to the Ministry of Public Health and to the 
drug manufacturers. The form for reporting adverse events is provided in Appendix 4: Serious 
Adverse Event Form. 
 
C.6. ASSESSMENT OF RESISTANCE 
Currently, two types of HIV resistance analyses are available: phenotypic and genotypic testing. 
Phenotypic testing assess the ability of specific drugs to inhibit viral replication in cultured cells, but 
are restricted to specialized laboratories and commercial companies due to their time-consuming 
and costly nature. Genotypic resistance tests assess the genetic composition of the reverse 
transcriptase and protease genes using PCR technology.  Following amplification, the genes are 
subjected to automated DNA sequencing to detect any mutations (Visible Genetics, ABI/Perkin-
Elmer, Affymetrix) or point mutation assays (Innogetics and Chiron). 
The relative simplicity and reliability of the genotypic assay used to determine drug-related 
mutations makes it more feasible than any of the phenotypic assays for initial, real-time 
measurement of resistance in this study. Several laboratories in Thailand have expertise in 
genotypic resistance testing and were trained by our group at Harvard (Chulalongkorn and Mahidol 
Universities). These tests are presently done for research purposes only. We anticipate that, 
although real time resistance testing will not be feasible in this trial and is not likely to become part 
of the standard care in Thailand in the short term, for safety reasons batched genotypic resistance 
testing will be performed both in VL-S subjects who satisfy switching criteria because of virologic 
failure and in CD4-S subjects who satisfy switching criteria because of CD4 cell loss.  
New mutations associated with drug resistance are being discovered regularly. Exhaustive and 
regularly updated resistance patterns to antiretroviral drugs are made available by the International 
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AIDS Society-USA 57 (www.IASUSA.org). Resistance interpretation is complex and several groups 
provide regularly updated algorithms for analysis, including the Stanford HIV RT & Protease 
Sequence database 9 (hivdb.stanford.edu). 
Identification of primary and secondary protease and RT mutations will be carried out using the 
regularly updated consensus tables and algorithms from the International AIDS Society – USA 
Drug Resistance Mutations Group as well as Los Alamos and Stanford.  
In subgroup B strains, ZDV resistance emerges slowly over months/years through the selection 
and accumulation of mutations at many different RT codons 157.  The most important RT codon 
mutations cause substitutions at amino acids 41, 67, 70, 215, and 219. M184V causes high level 
(>100-fold) 3TC resistance. It emerges rapidly in patients receiving 3TC monotherapy and is 
usually the first mutation to develop in a failing 3TC-containing regimen. The multinucleoside 
resistance Q151M mutation confers intermediate levels of resistance to ZDV, ddI, d4T and ABC. It 
is generally followed by mutations at codons 62, 75, 77 and 116, which induce high-level 
resistance to each of these NRTIs.  For NNRTI a single mutation is enough to confer high-level 
drug resistance. K103N is the most clinically important NNRTI resistance mutation as it is sufficient 
to cause virological failure with any of the three existing NNRTI.  The V106A mutation causes >30 
fold resistance to NVP, intermediate resistance to DLV and low level of resistance to EFV.  
Resistance to PIs develops in a stepwise manner through the accumulation of mutations in the 
HIV-1 protease gene 119, 120. Primary PI mutations (such as G48V, V82A/T/F/S, M46I/L D30N, I84V 
and L90M) decreased binding of the PI to the protease and are generally the first to be selected. 
Secondary mutations can be compensatory to the primary mutation to improve viral fitness. 
Because the systematic study of both genotypic and phenotypic data on clinical isolates from large 
numbers of patients followed with carefully collected clinical data can reveal unsuspected patterns 
of mutations, we plan to collaborate with commercial companies to study the phenotypic HIV 
resistance patterns. This study will be designed and implemented as a separate, but connected 
project related to the trial [See Appendix 11, Letters of Collaboration].  In addition, it will be 
important for the interpretation of the study results to evaluate viral replication capacity (fitness), 
especially in the group under CD4-S 134. This will be done in a retrospective fashion, on stored 
frozen samples, comparing replication capacity at base line and at times of peak immunological 
response and immunological failure. As with the investigation of phenotypic resistance, 
collaborations will be sought, and it is likely that additional funding will be required. 
Sequencing of RT and protease genes will be performed using the HIV-1 Genotyping Systems kit 
(Applied Biosystems, Foster City, California, USA), according to the manufacturer’s guidelines. 
Experience in related projects (the U.S. ACTG and the World Health Organization (WHO) project 
for global surveillance of resistance) suggests that it is important to analyze and quality-control 
genotypic data in ways going beyond the checks built into the ABI system. One needs to determine 
the starting point of the sequence generated by lab equipment in each of the two genes of interest; 
to detect, document, and correct for frameshifts; to align the sequence in a way accounting for (and 
documenting) insertions and deletions; to detect illegal nucleotide codes and stop codons (both of 
which indicate quality problems in the sequence); to check for unusually high frequencies of 
mixture or ambiguous codes; to analyze sequences for signs of contamination; and to examine 
mutational patterns, double-checking abnormal results. Since subtypes vary, it is helpful to 
examine mutations in relationship to a reference wild type sequence that is of the same subtype as 
the one under analysis, and this implies determining which subtype that sequence belongs to 
(although the determination is necessarily approximate when only protease and RT data are 
available).   
Frontier Science and Technology Research Foundation provides data management (and through 
the Statistical Data Analysis Center located at Harvard, statistical analysis) for the ACTG. It is also 
the Data Center for the WHO global surveillance project, and in that role has been analyzing and 
organizing genotypic data from labs in Brazil, France, Israel, South Africa, Thailand, and Uganda. It 
has a comprehensive, web-based system for analyzing sequences, implementing the quality 
checks mentioned above, and will make that system available to this project, generating reports on 
each sequence. 
In addition, we will include a quality assurance program similar to the Virology Quality Assurance 
systems in the ACTG. We will submit to our colleagues at Frontier Science the sequence data 
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provided by the reference laboratory as well as those generated by our own laboratory to compare 
reports and make sure that our laboratory generates consistent results. 
 
C.7. COHORT RETENTION 
Patients will be followed at the hospital the family chose for the follow-up of the pregnancy, care of 
the child and HIV treatment. The process of informed consent counseling which involves 
explanation of the study objectives, potential risks and benefits before enrollment, as well as the 
ongoing counseling at each visit will be designed to ensure that patients understand the necessity 
for them to comply with the protocol requirements. Moreover, the family approach to HIV care and 
treatment is expected to facilitate adherence to the protocol. 
As in previous PHPT studies, patients are asked at each visit whether they have moved since their 
last visit or plan to move. In cases of missed scheduled appointments, the patients will be 
contacted by mail or phone, or visited by a social worker. In addition, patients will have access to 
the study clinic for counseling and care at any time throughout the study period and can reach the 
nurse in charge of their follow-up by telephone. When appropriate, patients can be reimbursed for 
transportation and medication costs. The DSMB will review enrollment, compliance, and study 
retention and make recommendations as appropriate. 
The study nurse will see patients every month for drug dispensation and adherence/tolerance 
evaluation and the physician every 3 months for clinical and biological evaluations. It is our 
experience that such frequent patient/medical team contact is very well accepted and essential for 
improving adherence, providing ongoing counseling and information, and preventing toxicities. 
 
C.8. RANDOMIZATION PROCEDURES 
We anticipate that 60% of the patients enrolled will be women. The study statistician will generate 
two randomization lists per site so that mothers and their partners are randomized separately. 
Each list, (by blocks of 4 to 8, depending on the expected site enrollment) will be composed of 
running randomization numbers. For example, each block of 8 numbers will include 4 numbers 
associated with VL-S and 4 associated with CD4-S. Block size will not be disclosed to the study 
site so that at no time a co-investigator can guess what will be the monitoring scheme of the next 
patient.  
As blinding in this trial is not feasible, randomization will be centralized and it will take place after 
the patient has been enrolled and the antiretroviral treatment has been started. Since the 
first treatment regimen is the same in both study arms, the investigator will not have to wait 
for randomization to start treatment When the enrollment has taken place, the co-
investigator will send a Declaration of new enrollment form to the Study Coordination 
Center specifying that the patient started the first line regimen. The Study Coordination 
Center will refer to the lists of randomized numbers for the site, assign the patient to the next 
number, and send a fax to the co-investigator specifying the patient number and the corresponding 
monitoring scheme.  
Case Report Forms for each study visit will be provided for each patient. Study participants will not 
be identified by name on any study documents but will be identified by a Patient Identification 
Number.  All laboratory specimens, evaluation forms and reports will only be identified by a coded 
number. All records will be kept in a locked file cabinet in the clinical research unit. All computer 
entry and networking programs will only be processed with coded numbers. Clinical information will 
not be released without the written permission of the patient.  
 
C.9. STUDY DRUG SUPPLY, DISTRIBUTION AND STORAGE  
Antiretroviral drugs for this trial will be supplied by the manufacturers in the form of study supplies 
and will be distributed to the study sites’ clinical co-investigators/pharmacists through the central 
pharmacy in Chiang Mai. The study pharmacist at the SCC supervises the management of stock, 
storage, dispatch of the study drugs, and ensures that they are properly pre-packaged and pre-
labeled. Study drugs will be stored in a locked cabinet devoted specifically to the study under the 
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responsibility of the hospital pharmacist. Each site pharmacist will maintain records of all study 
drugs received and their storage conditions. Pharmacists will return all unused or undispensed 
study drugs to the Chiang Mai study coordination center. 
 
C.10. STUDY MANAGEMENT  
All study monitors, data managers and clinical co-investigators have received training for human 
subject protection. 
The Study Coordination Center (SCC) team is responsible for the overall organization and 
monitoring of the study, in particular compliance with Good Clinical Practices (GCP) 158 and 
reporting to the sponsors, as well as data entry, data management and statistical analysis. Site co-
investigators are responsible for the medical management of the patients. Routine laboratory 
exams and procedures necessary for enrollment and follow-up of patients are done at each site. 
The PHPT laboratory is responsible for the centralized laboratory exams, viral loads, resistance 
testing, and samples repository. Quality control of the site laboratories is ensured in collaboration 
with the Faculty of Associated Medical Sciences, Chiang Mai University. 
The Study Coordination Center staff for PHPT includes a coordinator, a pharmacist, two clinical 
safety monitors, ten clinical research assistants, three data managers, four data entry technicians, 
five laboratory technicians, two logisticians, a translator and three secretaries. This team is well 
trained in the management of clinical trials in HIV/AIDS and their roles have been refined through 
the course of the PHPT studies. They are highly motivated and will be carried over to manage the 
proposed study and adapt the procedures developed for PHPT-1 and PHPT-2 to the new protocol. 
The study teams at each site will consist of physicians, nurses, laboratory technician, pharmacist 
and counselors, in addition to the investigators. Training of all research team members will take 
place in the initial period of the study, and will include sessions on HIV management and 
antiretroviral therapy, counseling, confidentiality, compliance and procedures designed for study 
implementation. This training has been proven useful to ensure compliance with GCP and to 
minimize loss to follow-up. 
Prior to the beginning the study, the manual of operation will have been translated into Thai and 
reviewed by all research team members. One training session will focus on the importance of high 
quality data collection and compliance to the protocol on the final study results. A bi-monthly 
newsletter/report will be used to highlight and further clarify these issues.  
Every form will pass through the following steps: completion; on-site checking by the clinical 
research assistant (CRA); tracking at SCC; review by the safety manager at SCC and investigation 
if necessary; double data entry; file comparison; and 100% verification. 
At their weekly visits, the CRA, under the supervision of the SCC, will monitor the quality and 
accuracy of data collected in the research records, and the concordance with source documents, 
and will check that all regulatory and clinical safety requirements are met. The data management 
team at the SCC will review all forms for completeness and any discrepant responses. In the case 
of incoherent or missing data, the study site team will be immediately contacted and, if necessary, 
the form returned to them for correction. The CRA will be responsible for obtaining answers to 
queries during the weekly site visits. 
The data entry and management programs, written by PHPT study statisticians in charge of data 
management, will be adapted for this proposed study. These programs check for duplicates and 
examine the dataset for range checks on each field within a form, consistency checks between 
fields on the same form, and between fields on different forms. All forms coming from the sites are 
recorded and filed upon arrival at the SCC. The tracking database in place at the SCC will provide 
updated information on each patient every week, as well as the total number of patients at each 
stage of follow-up. A program generates the list of missing pages/forms.  
The data managers generate queries until final validation of the CRFs. Validated CRFs serve as 
evidence that the history and clinical data has been recorded, and that all lab tests and procedures 
have been completed. An audit trail is maintained for all changes made to the original data set as 
required by GCP. There will be ongoing monitoring of the safety profile of each patient by the SCC 
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and all serious adverse events will be reported according to GCP. (Regular meetings will be 
organized with clinical investigators and their teams to review the study monthly reports).  
 
C.11. MAIN ENDPOINTS 
The primary endpoint is clinical failure defined as the occurrence of confirmed CD4 below 50, first 
or new AIDS-defining event, or death. The main secondary endpoint, related to the preservation of 
treatment options, is the number of drugs exhausted, taking into account cross-resistance 
mutations. 
 The quantitative measure of the therapeutic options left at a given time as determined by mutation 
pattern of the genotypic sequence of subject-patient derived virus will use the metric developed by 
Dr. V. De Gruttola and H. Y. Jeing for use in protocol A5115, denoted FD. First, the interpreting 
system for genotypic sequence data “Stanford Inferred Drug Resistance (beta test)” is used to 
determine which drugs the patient-derived virus is sensitive to. Then the number of classes of 
drugs that include at least one drug to which a patient's virus is sensitive is counted and denoted 
NC. If a subject's virus is sensitive to all drugs in NRTI class, 0.3 credit to NC is added; similarly, 
0.3 credit to NC for full PI class sensitivity is added. The resulting score is the value of FD. 
Note: Additional information will be generated and provided to the Resistance Experts Committee 
in order to complete the resistance data and cross check coherence with FD: the total genotypic 
sensitivity score (GSS) computed by adding, for each drug the patient is receiving, 1 if there is 
sensitivity or 0 if there is resistance; and the total number of mutations per the IAS-USA table, and 
the patient’s treatment history. 
 
The secondary endpoint related to safety will be time to the first development of grade 3 or grade 4 
sign, symptom, and laboratory abnormality. For secondary analysis, endpoints related to virological 
and immunological failure are defined as for switching criteria: VL above 400 copies per mL and 
30% CD4 decline from observed peak values within 200 cells from baseline. Note: failure to 
raise CD4 by more than 50 cells after one year of therapy in the presence of viral replication 
would be considered as an immunological failure. Similarly, failure to decrease VL below 
400 copies by 6 months would be considered as virological failure. In both cases, the 
“Resistance Experts Committee” would review the patients’ data and would advise on the 
most appropriate course of action for these patients.    
 
C.12. STATISTICAL CONSIDERATIONS 
C.12.1 General design issues. 
The proposed study is designed primarily to test the non-inferiority of the CD4 based monitoring 
strategy compared to the standard viral load based strategy. To be more precise, we would like to 
demonstrate that, given the expected advantages of using a simplified CD4 based monitoring 
strategy; this strategy does not lead to an unacceptably higher risk of clinical failure compared to 
the standard monitoring strategy. 
A very important secondary objective is to determine whether or not there is a benefit in terms of 
drugs spared, taking cross-resistance mutations and cross-toxicities into account, when using 
CD4-S instead of VL-S. 
 
C.12.2 Power and Sample Size.   
The study will test for non-inferiority between strategies, i.e. that at 3 years the risk of clinical failure 
under CD4-S (PCD4) is not higher than the risk of failure under VL-S (PVL) by more than a 
predefined difference, delta, considered clinically acceptable given the expected benefit of using 
the alternative strategy. CD4-S will be considered non inferior to VL-S for practical purposes if the 
upper limit of the confidence interval of the difference between PCD4 and PVL failure rates is smaller 
than delta 159. 
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The null hypothesis is that the difference of clinical failure rates between the CD4-S and VL-S arms 
is equal to or greater than delta (H0: PCD4 – PVL > delta) 159, 160. The alternative hypothesis is that 
failure rate under CD4-S relative to VL-S is inferior to delta (H1: PCD4-PVL< delta). 
The first type of error that we are concerned about is the declaration of non-inferiority of CD4-S 
compared to VL-S when the true difference in failure rates is equal to or greater than delta. 
Therefore, the non-inferiority test will be designed so that this risk is no more than 5%. Another 
potential class of error would be to conclude that the two monitoring schemes are not equivalent 
when the true difference between CD4-S and VL-S is less than delta. This would result in choosing 
to keep VL-S when the alternative CD4-S is not inferior. In this trial, the sample size will be such 
that the risk of missed non-inferiority is less than 20%, assuming PCD4  = PVL. 
For calculation of the sample size, a value for PVL must be assumed and an acceptable difference 
delta must be defined. Based on the review of the literature 11, 129, 130, 132, 161, we have hypothesized 
that in a population of ARV naïve patients without symptoms initiating HAART with CD4 count 
between 50 and 250, the risk per year of clinical failure under VL-S would be 5%, i.e. PVL 
approximately 14% after 3 years. With a value for delta set to 7.4%, which corresponds to a hazard 
ratio (Rate of failure under CD4-S relative to the rate of failure under VL-S) of 1.6, the sample size 
ensuring 80% power to detect non-inferiority of CD4-S is 304 evaluable patients.  
Because we are mostly interested by the comparison of PCD4 and PVL at three years when we will 
also be able to compare the strategies in terms of treatment options preserved, we have presented 
a non-inferiority test based on an absolute difference delta between failure rates. However, the 
fixed hazard ratio 1.6 will be used to determine the critical limit for non-inferiority testing for two 
important reasons. Firstly, use of a hazard ratio will be necessary for comparing clinical outcomes 
at interim analysis; secondly, a constant delta does not have the same meaning at different levels 
of clinical failure rates (Table 3). For example, a fixed difference of 8% represents a several fold 
risk increase when PVL is in the 1 - 2% range, while the same difference can become acceptable 
when PVL is higher than 10%.  
In order to investigate the consequences of a variation of PVL around the expected value of 14%, 
we have calculated the sample size for different values of PVL, hazard ratios (and corresponding 
delta), and power levels (table 3). 
Table 3: Number of evaluable patients per arm necessary to guarantee a 80 or 90% power in a 
one-sided non-inferiority test, according to PVL and the delta difference, corresponding to the 
predetermined hazard ratio.  
3 year VL-S Clinical 
Failure rate  
 10% 11% 12% 13% 14% 15% 16% 17% 18% 19% 
Hazard Ratio 1.5 Delta 0.046 0.050 0.054 0.059 0.062 0.066 0.070 0.074 0.077 0.081 
Power 90% 800 729 670 621 578 541 509 481 456 433 
Power 80% 587 535 492 455 424 397 373 352 334 317 
Hazard Ratio 1.6 Delta 0.055 0.060 0.065 0.070 0.074 0.079 0.083 0.088 0.092 0.096 
Power 90% 571 521 479 444 413 387 364 344 327 311 
Power 80% 420 383 352 326 304 284 268 253 239 228 
Hazard Ratio 1.7 Delta 0.064 0.070 0.075 0.081 0.086 0.091 0.097 0.101 0.106 0.111 
Power 90% 430 393 361 355 312 293 276 261 247 235 
Power 80% 318 290 277 249 230 215 203 192 182 173 
To meet the study objectives for the primary hypothesis, 608 evaluable patients or 700 enrolled 
patients assuming that 15% of the patients will not be evaluable, will be sufficient. However, based 
on the number of events observed at each interim analysis, the DSMB may recommend an 
adjustment of the sample size or of the duration of follow up.  
Table 4 shows the results of testing for non-inferiority of CD4-S versus VL-S with 304 evaluable 
patients in each arm, a hazard ratio of 1.6 (delta .074), a value for PVLof 0.14 and various values of 
PCD4. 
3 year VL-S Clinical Failure rate PVL .1400 .1400 .1400 .1400 .1400 
3 year CD4-S Clinical Failure rate PCD4 .1600 .1625 .165 .1675 .17 
95%CI Upper boundary of the difference of failure rates .0677 .0700 .0730 .0757 .0783 
Conclusion of CD4-S non inferiority No No No Yes Yes 
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With 1.6 as critical hazard ratio for non-inferiority and a 14% observed PVL, we see that CD4-S will 
be declared non inferior statistically with PCD4 equal to 16.5%, but will be declared inferior with PCD4 
equal to 16.75%.  
C.12.3 Data Monitoring 
As was done in PHPT-1 and -2, screening, accrual and safety data will be reviewed by the 
monitoring team every week. The protocol statistician will regularly report the results to the study 
team. A monthly study report with screening, accrual, and patient characteristics at entry and at 
each subsequent visit, as well as safety data (blind to randomized treatment assignments), will be 
issued throughout the duration of the study.  
 
C.12.4 Interim Monitoring 
This study will be monitored regularly for toxicity, compliance, and feasibility. Two interim efficacy 
analyses and one final analysis are planned. Monitoring of clinical failure rates will be conducted 
for patient safety. The trial will be discontinued if the clinical failure rate in the CD4-S group is 
clearly higher than in the VL-S group. 
The interim analysis will be based on comparison of the time to clinical failure curves using Kaplan-
Meier estimates and log rank statistics (one sided). For stopping rules, O'Brien-Fleming boundaries 
162 will be used to adjust for the multiple looks, as modified by Lan and Demets 163.  The two interim 
analyses will be conducted when approximately 33% and 67% of the expected number of clinical 
failures will have occurred. The Z statistics for stopping the study and final analysis are 2.9611, 
2.0938, and 1.7096. 
Therapeutic options left to patients according to the pattern of resistance acquired under each of 
the monitoring strategies is the most important secondary endpoint of this study and will be 
assessed for safety purposes at each interim analysis. Due to the complexity and rapid evolution of 
the field, genotyping information will be reviewed prior to interim review by the study statistician 
and a group of experts in resistance mutation testing/interpretation. At least one member of the 
DSMB will be a specialist in resistance mutations. Patterns of resistance mutations, number of 
drugs and classes used, as well as number of drugs remaining available based on the IAS-USA 
interpretation tables will be compared between groups. The metrics developed at Harvard will 
greatly facilitate this comparison as it quantifies, in a single measurement, the expected 
therapeutic options left for patients at any given time point which can then be analyzed using 
standard statistical methods [See Section C.13.Data and Safety Monitoring Board below]. 
The quantitative measure of future drug options (FD) based on mutational resistance pattern of 
patients derived virus is an ordered categorical variable which can take values of 0, 1, 1.3, 2, 2.3, 
2.6, 3, 3.3, or 3.6 if the three possible drug classes (NRTI, NNRTI, PI) are considered.  
Our colleagues at the HSPH Department of Biostatistics performed an exploratory analysis using 
genotypic data from ACTG 364, ACTG 372, ACTG 359, and ACTG 398 to investigate the 
properties of this endpoint in view of its utilization in protocol ACTG5115. The estimates of 
standard deviation of FD among HAART-experienced patient subjects appear highly consistent 
across the studies. The pooled data gives an estimate of standard deviation of FD 0.99, which can 
be assumed as the maximal standard deviation of FD in our study where all patients being 
antiretroviral naïve are assumed to present uniformly with the maximum score at study entry. At 
each interim analysis FD will be compared across the two strategy arms using a chi square test for 
ordinal categorical data with a two-sided 0.05 significance level 164. For those who are undetectable 
at the time of analysis we will use their last available genotypic testing, or the assumed maximum 
score at baseline. A one point deviation of the median FD would be considered of major clinical 
importance at the population level and would trigger an extensive review of the laboratory data by 
the resistance committee including patterns of virological (% above 400 copies/mL) and 
immunological failures (% with CD4 decline more than 30% within 200 cells from baseline), 
patterns resistance/cross resistance and drug toxicities/intolerance. 
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C.12.5 Analysis Plan  
All analysis will primarily follow the intent to treat philosophy. However, per protocol comparisons 
will also be performed in order to take into account protocol deviations and cohort retention. 
Primary analysis will compare the group randomized to CD4-S with the group randomized to VL-S 
based on the Kaplan-Meier estimates of the clinical failure rates at 36 months and their Greenwood 
standard error estimates.  As suggested by Makuch and Simon 165, monitoring scheme 
comparisons will be based on the confidence interval for the difference between the treatment 
failure rates. The upper 95% one-sided confidence boundary for the true difference in failure rates 
between CD4-S and VL-S will be calculated.  If this confidence boundary is less than the threshold 
value delta corresponding to a 1.6 hazard ratio, this will be taken as evidence that, from a clinical 
perspective, CD4-S is not inferior to VL-S.  In this case, we would be 95% confident that the failure 
rate under CD4-S is not higher than the failure rate under VL-S by more than delta.   
In a secondary analysis, confidence intervals of the failure rates will be provided to assess 
consistency of the overall result within patient stratum (women initiating therapy after delivery or 
partners).  
Time-to-event methods, including log rank tests, and Kaplan-Meier cumulative event curves will be 
used to summarize the major outcomes of new or recurrent disease progression, including death, 
and CD4 decline below 50.  
Although randomization will be the first step to balance known and unknown covariates between 
study arms, we will compare the distribution of all baseline characteristics among arms (chi square 
and Fisher's exact test when appropriate for qualitative variables, Wilcoxon for continuous 
variables). The analysis will be stratified on factors associated with the outcome such as clinical 
stage of disease, CD4 count, and viral load. For time to event outcomes, proportional hazards 
(Cox) models will be used to adjust statistical inferences for these factors. 
The most important secondary objective of this study is to evaluate the impact of switch strategies 
on viral resistance by comparing a quantitative measure of future drug options as determined by 
genotypic sequence data obtained across the two strategy arms. This comparison will use the 
specific metric developed by V. de Gruttola and H. Y. Jeing, Harvard School of Public Health as 
described in Section C.11 Main Endpoints and in Section C.13 Data and Safety Monitoring Board 
164. 
Other comparisons related to the preservation of treatment options between monitoring strategies 
will include the number of drugs used, taking into account cross-resistance mutations and cross 
toxicities; time to first switch and number of switches over the first 36 months follow-up period as 
well as the proportion of patients still on initial therapy. 
Time to first therapy change, virological and immunological failure under first line therapy will be 
studied in each arm using proportional hazard model (Cox) taking into account covariates such as 
viral load and CD4 count at entry, and adherence. This will allow the investigation of the role of 
baseline plasma HIV-1 RNA and CD4 measurements as predictors of treatment modifications, 
virological and immunological failure as well as the degree to which toxicity, noncompliance and 
viral genotype (treated like prognostic factors) also contribute to treatment modifications, virological 
and immunological failure. 
Depending on the number of drugs to which patients will be exposed, one could expect a 
difference in safety profile in relation to monitoring scheme. Clinical laboratory data and adverse 
experiences will be examined and will include plots of the data as well as summary statistics of the 
raw data and changes from baseline. Wilcoxon rank sum tests will be used to compare the groups 
for changes from baseline. The proportion of patients in each arm who experience toxicity will be 
compared using a two-sided Fisher's exact test. The proportion of patients in each arm reporting 
each individual type of adverse experience will be calculated. Differences in the severity of 
toxicities between groups will be evaluated, with each type tested at the P=0.05 two -sided level of 
significance. Due to multiple toxicity types, this evaluation will not represent a formal statistical test 
of a specific hypothesis. 
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Each of the statistical analyses on secondary endpoints will be conducted at the nominal .05 level 
of significance without adjustment for multiple comparisons. 
 
C.13. DATA AND SAFETY MONITORING BOARD  
Resistance Experts Committee. For patients assigned to the experimental arm (CD4-S), there is a 
potential for increased risk of resistance and cross-resistance, theoretically leading to fewer 
treatment options. For this reason, a Resistance Experts Committee will be constituted [See 
Appendix 11, Letters of Collaboration, for the members of this committee] consisting of experts in 
resistance mutations from USA, Thailand and Europe.  In order to track this problem, resistance 
mutations will be assessed in all patients with viral load > 400 copies/mL in the VL-S arm, all 
patients who fulfill criteria for switching in the CD4-S arm, plus a random sample of other subjects 
in the CD4-S arm so that measurable and comparable data can be analyzed from equivalent 
numbers in the two arms.  This will be done once a year and more often if deemed necessary by 
the DSMB. The Resistance Experts Committee will work independently from the research team 
and will provide expertise in support of the DSMB regarding the development of resistance 
mutations and their clinical implications. The Committee will be chaired by a member of the DSMB. 
Members of the Committee can be, but are not required to be, members of the DSMB because of 
logistical complexity. Members of the Committee will review closed interim reports, and the Chair of 
the Committee will have the responsibility to write the summary report of the Resistance Experts 
Committee deliberations and present that summary to the DSMB. The Resistance Committee does 
not make recommendations about the conduct of the study. In addition, depending on the specific 
patients’ treatment regimen and their pattern of virological/immunological response, individual 
clinical, virological, immunological and genotyping results may be submitted on an ongoing 
basis for individual safety purpose, in order to avoid an excessive accumulation of resistance 
mutations and to be able to modify therapy in a timely manner. It is anticipated that such case will 
be rare and will not affect the relevance of the study. 
Patterns of resistance mutations, number of drugs and classes used, as well as number of 
available drugs remaining based on the IAS-USA interpretation tables will be compared between 
groups by the study statistician. The committee will be asked to provide expert judgment according 
to current knowledge, including the criteria and methods developed by Dr. Victor de Gruttola at 
Harvard. If it appears that the patients enrolled in the CD4-S arm have a resistance pattern that 
significantly jeopardizes their future treatment options compared to patients in the VL-S arm, the 
DSMB will be advised of this and a DSMB meeting will be convened to provide further 
recommendations with regards to the conduct of the study. The resistance committee will meet at 
least every year or more often if deemed necessary. At the end of year three, should the 
committee conclude that a longer follow-up is necessary, the investigator will seek additional 
funding for an extension of the follow-up. 
Data Safety and Monitoring Board: The Data and Safety Monitoring Board (DSMB) has been 
specifically asked to evaluate safety and study parameters such as enrollment, compliance, follow-
up, laboratory evaluations, data submission, and quality control every six months throughout the 
course of the study. The DSMB will advise at each of these reviews whether the study should 
continue as originally designed. Efficacy analyses will be conducted for two interims and one final 
evaluation. The interim analyses will be presented to the DSMB when 33% and 67% of the 
expected number of clinical failure will have occurred. The DSMB will consist of five members, 
three of whom will be Thai. Three will be physicians and two statisticians, with at least one 
specialist of genotypic resistance mutations interpretation (the Chair of the Resistance Experts 
Committee).  None of the DSMB members will be directly involved in the conduct of the study. All 
meetings will take place in Thailand. A DSMB composed of five members, three of them Thais, has 
overseen the conduct of each of the two previous PHPT studies. These groups have functioned 
efficiently and have successfully played their role as an independent body, advising the research 
team on the best interest of the patients and the best conduct of the study. 
C. 14 PHARMACOKINETIC SUB-STUDY 
The second line HAART regimen in this study contains IDV/RTV, bid. The pharmacokinetics of 
ZDV, ddI, and 3TC are linear within the range of dosing used in clinical practice. The 
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pharmacokinetics of zidovudine (ZDV) has been investigated in both Caucasians and Thais and no 
marked ethnic difference in ZDV phosphorylation was observed. 3TC and ddI have been used in 
Thailand and no unexpected toxicity was reported.  The pharmacokinetics of IDV, in contrast, is not 
linear. With 800 mg tid dosing, it has been found to be similar in Thai and Caucasian patients. 
Safety and efficacy of IDV (800 mg, tid) versus IDV/RTV (800 mg/100 mg, bid) were found to be 
equivalent in both European and Thai populations, although there was a slight trend towards more 
adverse events in the bid arm in Thai patients. Indeed, the trough concentrations (Cmin) of 
IDV/RTV 800mg/100mg bid are significantly higher than in IDV 800 mg tid (1,400 ng/ml and 130 
ng/ml respectively), and the AUC is two fold higher in the bid regimen. Recently, IDV/RTV (400 
mg/100 mg, bid) has been reported to be well tolerated, with median IDV concentrations at day 15 
falling within the therapeutic range (Trough levels higher, peak level lower, AUC equivalent). 
To assess the inter-individual variability of drug levels, data will be collected in the first 20 patients 
participating in the randomized study and consenting for this substudy. In these patients, blood 
samples will be drawn one and two months after initiating the first line HAART regimen at predose 
and 1, 2.5, 4 and 12 h after ingestion of the study treatment. 
For each drug at each dosing, we will estimate the trough concentration (Cmin), time to maximum 
concentration (Tmax), maximum drug concentration (Cmax), elimination half-life (T1/2), area under 
the concentration time curve (AUC) and oral clearance (CL/F). We will estimate all the PK 
parameters using a population approach. Pharmacokinetic calculations will be performed using 
NONMEM V. 
To relate drug exposure (adherence, pharmacology) to the patient’s outcome, we will 
assess the plasma antiretroviral drug levels after one month of a new therapy in blood 
samples drawn for the regular follow-up of the patients. The assessment of plasma drug 
levels can also be performed in other samples, drawn at any time for the immunological and 
virological follow up. 
 
C.15. ARV MANAGEMENT STRATEGY FOR IMPLEMENTATION IN THE THAI CONTEXT 
An important public health objective of this study is to document HAART monitoring strategies in 
order to help their implementation in the Thai context, more specifically within the mother and child 
health framework. 
This trial, while testing two monitoring strategies, one simpler than the other, will at the same time 
involve, in both arms, intense and frequent clinical assessments as well as complex retrospective 
analysis (e.g. viral fitness assays and genotypic resistance mutations). We realize that these labor-
intensive components of the trial will not, in all likelihood, be directly applicable as standard of care. 
Yet, this trial will provide the necessary empirical evidence for designing future monitoring 
schemes appropriate to the various Thai contexts. The results and, more generally, the data 
generated in this trial will have to be put into practice, in particular with regard to the optimal 
frequency of evaluations, the relative importance of clinical, CD4 and viral load monitoring, the 
screening and management of metabolic/hematological toxicities and intolerance, the 
assessment/reinforcement of adherence, and the role of couple counseling for improved patient 
management.  
Investigating implementation of HAART in the Thai context is critically important as it coincides with 
the MOPH officially launching its new program “Expanding HIV care or treatment for Families” 
(Division of AIDS, Department of Communicable Diseases Control and Bureau of Health 
Promotion, Department of Health, December 21, 2001). Along with PHPT, colleagues from the 
Thai-US CDC collaboration, the MOPH Departments of Communicable Diseases Control and 
Health and Provincial Health Offices participated in the first workshop for the development of this 
program. PHPT was specifically asked to help design a model for the delivery of HAART therapy 
within the existing Mother and Child Health framework. The year 2002-3 development plan 
includes the assessment of the clinical, laboratory and psychosocial infrastructure of the program, 
the review of adult and pediatric OI and HIV treatment guidelines as well as the establishment of a 
consensus on the management of asymptomatic and symptomatic women, partners, and children.  
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A training and capacity building program will be initiated and appropriate monitoring and evaluation 
tools developed. 
We will collaborate with the Ministry of Public Health, in particular its Health Systems Research 
Institute, to develop the framework for data collection and analysis at the hospital level that will 
help shape policy decisions regarding HAART management strategies.  
C.16. STUDY TIMETABLE 
Table 5.  Study timetable 
Month of Study -6 0 6 12 18 24 30 36 42 48 54 60  
Study preparation  (Manual of Operation 
and CRFs, study drug, sites) 
4             
Randomization  4 4 4 4 4        
Patients on study drug  4 4 4 4 4 4 4 4 4 4 4  
Last patient visit        4 4 4 4 4  
Virological Studies   4 4 4 4 4 4 4 4 4 4  
Data Management   4 4 4 4 4 4 4 4 4 4 4
Interim and Final analyses    4   4     4  
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